公开(公告)号：US20130243692A1

公开(公告)日：2013-09-19

申请号：US13897676

申请日：2013-05-20

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Brian Der-Hua Lu ,  Siu-Long Yao ,  Cynthia Seidel-Dugan ,  Yan Wang

IPC: A61K51/04

CPC classification number: A61K51/0491

Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.

Abstract translation: 本发明涉及通过测定肿瘤葡萄糖代谢水平来评估IGF1R抑制剂如抗IGF1R抗体在治疗尤文氏肉瘤肿瘤中的功效的方法。 肿瘤葡萄糖代谢通过本领域已知的几种方法中的任一种包括FDG-PET / CT扫描在治疗方案的早期确定。

公开(公告)号：US20140336222A1

公开(公告)日：2014-11-13

申请号：US14339925

申请日：2014-07-24

Applicant: Merck Sharp & Dohme Corp.

Inventor： Stephane L. Bogen ,  Yao Ma ,  Yaolin Wang ,  Brian Robert Lahue ,  Latha G. Nair ,  Manami Shizuka ,  Matthew E. Voss ,  Margarita Kirova-Snover ,  Weidong Pan ,  Yuan Tian ,  Bheemashankar A. Kulkarni ,  Craig R. Gibeau ,  Yuan Liu ,  Giovanna Scapin ,  Diane Rindgen ,  Ronald J. Doll ,  Timothy J. Guzi ,  Danny J. Hicklin ,  Amin Nomeir ,  Cynthia Seidel-Dugan ,  Gerald W. Shipps, JR. ,  Malcolm MacCoss

IPC: C07D401/14 ,  C07D409/14

CPC classification number: C07D401/14 ,  C07D409/14

Abstract: The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Abstract translation: 本发明提供本文所述的式1的化合物或其药学上可接受的盐，溶剂合物或酯。 该化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的方法。